Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04626 (erbB-2)
 5,251 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In previous studies of the expression and organization of proto-oncogenes in human breast a significant correlation has been found between amplification of c-myc and c-erbB-2 genes in carcinomas and poor short-term prognosis. Gene expression was estimated by analysis of total RNA from tissues, and similarly assessment of gene organization relied upon extraction of DNA from tissues. The present study has compared the expression of c-myc and c-erbB-2 mRNA as determined by in situ hybridization, and c-myc and c-erbB-2 protein expression detected by immunohistochemistry in a group of carcinomas for which there was knowledge of genomic organization and/or expression. Formalin-fixed, paraffin-embedded tissues of 38 carcinomas were assessed for the presence of c-myc protein, and 13 of these were examined for c-myc mRNA by in situ hybridization. Similarly processed tissue from 14 tumours was tested for c-erbB-2 protein using the antiserum 21N and ten of these carcinomas studied for c-erbB-2 mRNA localization. There was a good correlation between gene amplification, the presence of c-erbB-2 protein and mRNA: both the latter were detected in six of the seven carcinomas with an amplification but in none without. For some carcinomas there was a good correlation between c-myc protein and mRNA levels. Three carcinomas with gene amplification had a lower percentage of cells with detectable protein than showed hybridization for mRNA. Other carcinomas had a lower level of mRNA expression than protein. Neither approach could predict which carcinomas had amplification of the c-myc gene.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas. 256 35

It is a matter of debate whether the amplification of c-erbB-2 oncogene or production of the oncoprotein in breast cancers correlate with the presence of lymph node metastasis and with a poor prognosis. This study was aimed at elucidating the immunohistochemical localization of oncogene products which are related to cell growth, c-erbB-2 product, epidermal growth factor receptor (EGFR), c-myc protein and estrogen receptor (ER), in benign and malignant lesions of the breast. Fresh frozen sections of 25 breast cancers and 11 fibroadenomas from Japanese women were studied by indirect immunoperoxidase method with proper fixation. C-erbB-2 product and EGFR were localized on the cell membrane whereas c-myc protein and ER were observed in the nuclei. Immunohistochemical expression of oncogene products and ER were not only observed in the mammary carcinomas but also in the fibroadenomas. However immunoreactivities of EGFR and ER were more frequently seen in the fibroadenomas (p less than 0.05). In breast cancers, the incidence of immunoreactivity for c-erbB-2 was higher in the cases with lymph node metastasis than cases without nodal metastasis (p less than 0.05) and there was reciprocal correlation between the expressions of EGFR and ER (p less than 0.05). Regarding the size of the primary tumour, there was no statistically significant correlation with the expressions of c-erbB-2, EGFR, c-myc or ER. Histological grade correlated only with the expression of ER (p less than 0.05).
 ...
PMID:Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma. 257 92

In order to get a better understanding of expressions of multiple oncogenes and their possible roles in human hepatocarcinogenesis, 379 cases of liver tissues were investigated immunohistochemically. EGF receptors were immunolocalized mainly in the sinusoidal endothelial cells. They might not take part in the development of hepatocellular carcinoma (HCC), c-myc protein was showed to be expressed in cancer cells and the hepatocytes in the so-called "large-cell dysplasia" and in ductular metaplasia (DM). Its expression was also observed in some zone II hepatocytes of hepatic accini in 21% of normal liver tissues, which indicated that c-myc expression might also be related to the proliferation of mature hepatocytes. The positivity rate of c-erbB-2 product was shown to be highest among the oncogenic genes examined in this study. The positivity was observed in small polygonal liver cells (SPLCs) and the hepatocytes were observed in SCD and in DM. The expression level of c-erbB-2 oncogene in HCC cells was higher significantly than in normal hepatocytes, but lower than in SPLCs, the hepatocytes in SCD and in DM. We suggest that c-erbB-2 gene activation may play an important role not only in HCC genesis, but also in DM. Insulin-like growth factor II (IGF II), an oncofetal hepatocellular growth factor, was immunolocalized in the cancer cells, SPLCs and the hepatocytes in SCD, which indicated that activation and hyperexpression of IGF II gene might be responsible for the prominent proliferation of SPLCs and SCD, a crucial step in malignant transformation of hepatocytes.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Expression of c-myc, c-erbB-2, insulin-like growth factor II andepidermal growth factor receptor in hepatitis B, cirrhosis and hepatocellular carcinoma]. 778 Aug 18

The aims of this study were to assess the expression of protein products of c-myc, erbB-2, p53 and nm23-H1 gene in benign and malignant breast lesions, to estimate their possible coexpression and to correlate the results of immunohistochemical analysis with various clinicopathologic parameters. The method used was the immunohistochemical detection of the corresponding protein. Expression of c-myc protein was high in both malignant and benign lesions (95% and 100%). Expression of erbB-2 and mutated p53 proteins in malignant lesions was 27% and 34%. These proteins were present in benign lesions as well: 7.8% of benign lesions were positive for erbB-2 protein and 19.6% for p53 protein. The expression of nm23-H1 protein was similar in benign and malignant lesions: 47% and 54%. The coexpression of nm23-H1 and mutated p53 protein was found in 14 carcinomas (16.5%). We found a tendency of negative correlation between the expression of these two proteins. We also found a negative correlation between the size of breast carcinomas and the expression of nm23-H1, a higher proportion of nm23-H1-positive carcinomas in the group of erbB-2-negative, p53-negative carcinomas and a higher proportion of nm23-H1-positive carcinomas in the group of malignant lesions with negative axillary lymph nodes. Our results support the hypothesis that in women with breast cancer the expression of nm23-H1 gene may contribute to more favorable phenotype. We also showed that some changes found in malignant breast tumors such as the presence of mutated p53 protein and the expression of erbB-2 protein may be found in benign lesions as well.
 ...
PMID:Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters. 1600 11